A share price of Genmab ADR [GMAB] is currently trading at $21.86, up 1.30%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The GMAB shares have gain 6.95% over the last week, with a monthly amount drifted -1.75%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Genmab ADR [NASDAQ: GMAB] stock has seen the most recent analyst activity on April 01, 2025, when Bernstein downgraded its rating to a Underperform. Previously, William Blair upgraded its rating to Outperform on March 11, 2025. On February 13, 2025, upgrade upgraded it’s rating to Outperform but maintained its price target of $27 on the stock. Redburn Atlantic started tracking the stock assigning a Buy rating. JP Morgan downgraded its rating to Neutral for this stock on August 20, 2024. In a note dated July 15, 2024, RBC Capital Mkts upgraded an Outperform rating on this stock.
Genmab ADR experienced fluctuations in its stock price throughout the past year between $17.24 and $28.56. Currently, Wall Street analysts expect the stock to reach $45 within the next 12 months. Genmab ADR [NASDAQ: GMAB] shares were valued at $21.86 at the most recent close of the market. An investor can expect a potential return of 105.86% based on the average GMAB price forecast.
Analyzing the GMAB fundamentals
Trailing Twelve Months sales for Genmab ADR [NASDAQ:GMAB] were 3.23B which represents 18.64% growth. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at 0.34%, Pretax Profit Margin comes in at 0.43%, and Net Profit Margin reading is 0.37%. To continue investigating profitability, this company’s Return on Assets is posted at 1.02, Equity is 0.26 and Total Capital is 1.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.63 points at the first support level, and at 21.39 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.00, and for the 2nd resistance point, it is at 22.13.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Genmab ADR [NASDAQ:GMAB] is 5.34. As well, the Quick Ratio is 5.32, while the Cash Ratio is 2.14. Considering the valuation of this stock, the price to sales ratio is 4.16, the price to book ratio is 2.62 and price to earnings (TTM) ratio is 12.40.
Transactions by insiders
Recent insider trading involved Klimovsky Judith V, Director, that happened on Jun 17 ’25 when 1300.0 shares were purchased.
